The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:2268-2269 December 4, 2003 Number 23
NextNext

Structured Treatment Interruption for Patients with Human Immunodeficiency Virus Infection

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Hirschel, B.
-Related Article
by Lawrence, J.
-PubMed Citation
To the Editor: The study by Lawrence et al. (Aug. 28 issue)1 demonstrates that continued treatment with an optimized antiretroviral regimen is superior to an interruption in treatment for patients with multidrug-resistant human immunodeficiency virus (HIV) infection. In my view, this study raises some important ethical issues. No study, at any time, has demonstrated the superiority of treatment interruption over conventional anti-HIV therapy. Moreover, because of concern about clinical progression and HIV resistance, treatment interruption has consistently been discouraged in current and previous guidelines.2 Therefore, the authors' hypothesis of a 33 percent reduction in the incidence of progression of disease . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.